Diterpene compound and application thereof

By preparing tritinyl and using biosynthesis technology, the problems of limited sources of tritinyl diterpenes and difficulty in synthesis have been solved, and the development of biosynthetic and anti-tumor drugs have been realized, providing new drug development pathways.

CN119019216AActive Publication Date: 2024-11-26INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310611383.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26
Estimated Expiration
2043-05-26

AI Technical Summary

Technical Problem

The source of tristinyl diterpenes has a limited amount and is of low content, and it is difficult to chemical synthesis, resulting in limited drug development and application. No biosynthesis research has been reported.

Method used

Cephalotene is discovered and prepared as a key precursor for biosynthesis of tridentine diterpenes. The compound is catalyzed by specific diterpenes synthase, and produced by biofermentation and molecular biology techniques. , further post-modification is performed through enzyme catalytic reaction to prepare diterpene derivatives with anti-tumor activity.

Benefits of technology

Biosynthetic methods are provided to obtain raw materials and intermediates for tristinyl diterpenes, and new drugs with anti-tumor activity have been developed, which solves the problems of limited sources and synthesis difficulties, and promotes the possibility of its drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019216A_ABST
    Figure CN119019216A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of natural product chemistry, and relates to a novel diterpenoid compound which has a structure as shown in a formula I and is named as cephalotene. The compound provided by the invention is a mother nucleus structure of cephalotaxane diterpenoid represented by cephalotaxus hainanensis lactone, is a common key precursor for biosynthesis of cephalotaxane diterpenoid compounds, and provides a raw material / intermediate for obtaining cephalotaxus hainanensis lactone and other cephalotaxane diterpenoid compounds; meanwhile, various compounds with human-derived tumor cytotoxic activity can be obtained through derivatization of the diterpenoid compound, and the diterpenoid compound is expected to be developed into anti-tumor drugs. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention belongs to the field of natural product chemistry, and specifically relates to a new diterpene compound and application thereof. Technical background:

[0002] Harringtonolide (also known as hainanolide) is a diterpene compound with a 6 / 6 / 5 / 7 tetracyclic rigid skeleton and highly oxidized harringtonia complex structure discovered in the 1870s from Cephalotaxus plants. It includes a cycloheptatrienone structural unit and contains multiple chiral centers in the molecule. It has anti-tumor, anti-inflammatory and antiviral activities (Buta JG, Flippen JL, Lusby WR. Harringtonolide, a plant growth inhibitorytropone from Cephalotaxus harringtonia (Forbes) K. Koch. Journal of Organic Chemistry, 1978, 43 (5), 1002-1003. Sun Nanjun, Xue Zhi, Liang Xiaotian, et al. Study on the structure of Hainanolide, a new anticancer active ingredient. Acta Pharmaceutica Sinica, 1979 (1). Ni L, Zhong XH, Chen XJ, Zhang BJ, Bao MF, Cai X H. Bioactive norditerpenoids from Cephalotaxus fortuneivar.alpina and C.lanceolata. Phytochemistry, 2018, 151, 50-60.). So far, more than 80 compounds of this type have been reported ( Figure 1), collectively referred to as cephalotane-type diterpenoids (Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua H M. Progress in structure, synthesis and biological activity of natural cephalotane diterpenoids. Phytochemistry, 2021, 192, 112939. Ge ZP, Zhou B, Zimbres FM, Cassera MB, Zhao JX, Yue JM. Cephalotane-Type Norditerpenoids from Cephalotaxus fortuneivar. alpina. Chinese Journal of Chemistry, 2022, 40(10), 1177-1184.).

[0003] At present, the cephalotaxane diterpenoid compounds are only found in the genus Cephalotaxane, with limited sources and low content. Although the chemical synthesis of this type of compound has been reported, due to its complex structure and multiple chiral centers, it is difficult to synthesize, the route is long, the yield is low, and there is no commercial application value. In addition, chemical synthesis often uses toxic reagents, causing environmental pollution, etc., which limits its application. (Xu L, Wang C, Gao Z, Zhao YM. Total Synthesis of (±)-cephanolides B and C via a Palladium-catalyzed cascade cyclization and late-stage sp3 C–H bond oxidation. Journal of American Chemical Society, 2018, 140, 5653-5658. Zhang H, He H, Gao S. Asymmetric total synthesis of cephanolideA.Angewandte Chemie International Edition,2020,59,20417-20422.Zhang H,He H,Gao S.Asymmetric total synthesis of cephanolide B.Organic Chemistry Frontier,2021,8,555-559.Haider M,Sennari G,Eggert A,Sarpong R.Total synthesis of theCephalotaxus norditerpenoids(±)-cephanolides A–D.Journal of AmericanChemical Society,2021,143,2710-2715.Ao Q,Zhang HJ,Zheng J,Chen X,ZhaiH.Asymmetric total synthesis of (+)-mannolide C.Angewandte ChemieInternational Edition,2021,60,21267-21271.Ren Z,Sun Z,Li Y,Fan X.Total synthesis of(+)-3-deoxyfortalpinoid F,(+)-fortalpinoid A,and(+)-cephinoid H.Angewandte Chemie International Edition, 2021, 60, 18572-18576. Li A, He Z, Liu B, Yang Z, Zhang Z. Stereoselective synthesis of (±)-cephanolideB. Organic Letters, 2021, 23, 9237-9240.). .

[0004] In summary, the sources of this type of compound are limited, which restricts its development and application as a drug. Biosynthesis can provide an effective means to solve this problem. However, there is still no report on its biosynthesis research. The biosynthesis of this type of compound is based on geranylgeranyl pyrophosphate (GGPP) as a precursor, and diterpene nucleus compounds are generated under the catalysis of diterpene synthase, and then Hainan quinoline lactone and its analogs are generated under the catalysis of multiple post-modification enzymes. At present, the diterpene nucleus compounds of this type of compound have not been reported.

[0005] Therefore, the discovery and preparation of diterpene core compounds, which are key precursors for the biosynthesis of cephalotaxane diterpenoids such as cephalotaxane lactone, will provide raw materials / intermediates for the synthesis of cephalotaxane diterpenoids such as cephalotaxane lactone with anti-tumor and other medicinal values ​​using biosynthetic methods, and has potential application value. Summary of the invention

[0006] In a first aspect, the present invention provides a novel diterpenoid compound having a structure as shown in Formula I:

[0007]

[0008] The compound provided by the present invention is a parent core structure of a cephalotane diterpene represented by hainanese truncatula lactone, and is a key precursor for the biosynthesis of cephalotane diterpene compounds. The present invention names the compound as cephalotene, with an English name of cephalotene.

[0009] The compound provided by the present invention can be obtained by enzymatic reaction using geranylgeranyl pyrophosphate (GGPP) as a substrate and a specific diterpene synthase; the diterpene synthase has an amino acid sequence as shown in SEQ ID NO.1, or has an amino acid sequence that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:1 and has the activity of catalyzing the generation of diterpene compounds, or can be a truncated version of the diterpene synthase having the above amino acid sequence (such as removing the signal peptide). Based on the determination of the substrate and the amino acid sequence of the diterpene synthase, the compound can be produced by biological fermentation and with the help of conventional techniques in the field such as molecular biology, biochemistry, organic chemistry, etc.

[0010] In a second aspect, the present invention provides use of a compound having a structure as shown in Formula I in the preparation of diterpene derivatives, wherein the compound is used as a raw material for the preparation of diterpene derivatives.

[0011] The diterpenoid derivatives of the present invention may be natural products isolated from plants, preferably from Cephalotax plants, including all cephalotane diterpenoid compounds (cephalotane-type Norditerpenoids from Cephalotaxus fortuneivar.alpina. Chinese Journal of Chemistry, 2022, 40 (10), 1177-1184) reported in the literature (Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua H M. Progress in structure, synthesis and biological activity of natural cephalotane diterpenoids. Phytochemistry, 2021, 192, 112939) and the literature (Ge ZP, Zhou B, Zimbres FM, Cassera MB, Zhao JX, Yue JM. Cephalotane-Type Norditerpenoids from Cephalotaxus fortuneivar.alpina. Chinese Journal of Chemistry, 2022, 40 (10), 1177-1184). diterpenoids), such as Hainan crude torreya lactone, etc., and also include other natural diterpenoids with a trihalomethane core structure that have not been reported.

[0012] The diterpene derivatives of the present invention may also be non-natural compounds artificially synthesized using the compound shown in Formula I as a raw material, such as monohydroxylation or dihydroxylation based on the structure shown in Formula I.

[0013] The diterpene derivatives of the present invention may have a carbon skeleton structure as shown in Formula I. In other diterpene derivatives, the carbon skeleton may undergo carbon reduction (such as removal of methyl), carbon-carbon bond cleavage, carbon chain shift or skeleton rearrangement based on the structure shown in Formula I.

[0014] The diterpene derivatives of the present invention can undergo one or more of the following derivatizations based on the carbon skeleton: hydroxylation, carbonylation, carboxylation, esterification, epoxidation, hydrogen removal, aromatization, glycosylation, methylation, acylation, prenylation, reduction, etc.

[0015] The application of the present invention can specifically be to use the compound shown in formula I as a raw material and adopt chemical synthesis and / or biological synthesis methods to prepare diterpene derivatives.

[0016] The chemical synthesis method of the present invention can be carried out using principles, raw materials and reaction conditions known in the field of organic chemistry.

[0017] The biosynthesis method of the present invention is to use the compound shown in formula I as a substrate to carry out an enzyme catalytic reaction. The enzyme used in the enzyme catalytic reaction can be selected from: oxidase, reductase, glycosyltransferase, methyltransferase, acyltransferase, isopentenyltransferase, etc. Among them, the oxidase can be specifically selected from dehydrogenase, monooxygenase (such as cytochrome P450 enzyme) or dioxygenase (α-ketoglutarate-dependent dioxygenase).

[0018] The enzyme catalytic reaction can be carried out using a single enzyme, or by combining multiple enzymes, or by using synthetic biology methods and design concepts. The multiple enzyme combinations can be multiple enzyme combinations with different catalytic principles and types, such as oxidase and glycosyltransferase combinations, oxidase and methyltransferase combinations, oxidase and acyltransferase combinations, etc.; they can also be multiple enzyme combinations with the same catalytic principle, such as multiple enzyme combinations of different subfamilies in cytochrome P450 enzymes, or multiple enzyme combinations of cytochrome P450 enzymes belonging to the same subfamily but with different primary structures. The synthetic biology methods and design concepts can use different synthetic elements, devices, and modules to construct artificial pathways in microorganisms (such as Escherichia coli, Saccharomyces cerevisiae), plants (such as Nicotiana benthamiana), and animal cells (such as insect cells) through design, and use cell factories for biosynthesis.

[0019] As is well known in the art, the general biosynthesis pathway of diterpenoid natural products is: diterpene synthase catalyzes the cyclization of GGPP to generate diterpene skeleton compounds, and then a series of post-modifications occur on the skeleton compounds to generate diversified derivatives. Take the typical diterpene taxane compounds as an example: the first directional reaction step in the biosynthesis pathway of such compounds is the cyclization of GGPP catalyzed by taxadiene synthase, which generates the unique skeleton structure of taxane compounds "taxane-4 (5), 11 (12) -diene"; the downstream pathway after the core skeleton is formed includes further modifications at multiple sites of the core skeleton, including hydroxylation, acylation, carbonylation, formation of propylene oxide, side chain assembly, etc., and finally generates a series of taxane derivatives including paclitaxel. Therefore, those skilled in the art can understand that based on the mother core structure of the truncatane diterpene shown in Formula I provided by the present invention, a series of post-modifications can be performed by conventional biosynthetic means using enzymes with specific functions to obtain truncatane diterpene derivatives with corresponding functional groups or derivative structures.

[0020] In a third aspect, the present invention provides the use of a compound having a structure as shown in Formula I or a diterpene derivative thereof in the preparation of an anti-tumor drug.

[0021] The diterpenoid derivatives of the present invention may be natural products isolated from plants, preferably from Cephalotax plants, including all cephalotane diterpenoid compounds (cephalotane-type Norditerpenoids from Cephalotaxus fortuneivar.alpina. Chinese Journal of Chemistry, 2022, 40 (10), 1177-1184) reported in the literature (Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua H M. Progress in structure, synthesis and biological activity of natural cephalotane diterpenoids. Phytochemistry, 2021, 192, 112939) and the literature (Ge ZP, Zhou B, Zimbres FM, Cassera MB, Zhao JX, Yue JM. Cephalotane-Type Norditerpenoids from Cephalotaxus fortuneivar.alpina. Chinese Journal of Chemistry, 2022, 40 (10), 1177-1184). diterpenoids), such as Hainan crude torreya lactone, etc., and also include other natural diterpenoids with a trihaloline core structure that have not been reported. The diterpenoid derivatives of the present invention can also be non-natural compounds obtained by artificial synthesis of compounds shown in formula I as raw materials, such as monohydroxylation or dihydroxylation based on the structure shown in formula I.

[0022] The diterpene derivatives of the present invention may have a carbon skeleton structure as shown in Formula I. In other diterpene derivatives, the carbon skeleton may undergo carbon reduction (such as removal of methyl), carbon-carbon bond cleavage, carbon chain shift or skeleton rearrangement based on the structure shown in Formula I.

[0023] The diterpene derivatives of the present invention can undergo one or more of the following derivatizations based on the carbon skeleton: hydroxylation, carbonylation, carboxylation, esterification, epoxidation, hydrogen removal, aromatization, glycosylation, methylation, acylation, prenylation, reduction, etc.

[0024] The anti-tumor drug of the present invention may be a drug having cytotoxic activity against human cancer cells such as liver cancer, gastric cancer, colon cancer and / or cervical cancer. In addition, a large number of documents (such as Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua H M. Progress in structure, synthesis and biological activity of natural cephalotanediterpenoids. Phytochemistry, 2021, 192, 112939, etc.) clearly report the anti-tumor activity of various natural derivatives of the compound shown in Formula I.

[0025] Additional Notes

[0026] Unless otherwise specified, the scientific and technological terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The present invention may also be implemented using any methods and materials similar to or equivalent to those described herein, and specific implementation methods and preferred methods and materials are described herein without limiting the present invention in any way.

[0027] Beneficial technical effects

[0028] The compound provided by the present invention is a parent nucleus structure of a cephalotaxane diterpene represented by hainan truncatula lactone, and is a key common precursor for the biosynthesis of cephalotaxane diterpene compounds, providing a raw material / intermediate for obtaining cephalotaxane diterpene compounds such as hainan truncatula lactone by biosynthesis and / or chemical synthesis means or by combining the two means. At the same time, the diterpene compound and its derivatives have cytotoxic activity against human tumor cells such as liver cancer, gastric cancer, colon cancer, cervical cancer, etc., and are expected to be developed into a new type of anti-tumor drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 , representative 6 / 6 / 5 / 7 tetracyclic skeleton of Cephalotaxane diterpenoid compounds from Cephalotaxus plants;

[0030] Figure 2 , GC-MS analysis spectrum of Cephalotaxene; a, gas chromatogram of Cephalotaxene (peak C); b, EI-MS mass spectrum of Cephalotaxene. DETAILED DESCRIPTION

[0031] The following examples are provided to further illustrate various aspects of the present invention. These examples are non-limiting and should not be construed as limiting any aspect of the present invention. The scope of protection of the present invention is limited only by the claims. Without departing from the scope of the claims, those skilled in the art may make various modifications and improvements to various aspects of the present invention, and these modifications and improvements also belong to the scope of protection of the present invention. For example, replacing the promoter and expression vector used in the examples with other promoters and expression vectors commonly used in the art is something that can be understood and implemented by those of ordinary skill in the art.

[0032] In addition, it should be noted that, unless otherwise specified, the various materials and reagents used in the following examples are commonly used materials and reagents in the art and can be obtained through conventional commercial channels; the methods used are conventional methods known to those skilled in the art.

[0033] Example 1: Cloning of CsCTS gene

[0034] 1. Extraction of total RNA and synthesis of first-chain cDNA

[0035] Select appropriate amount of Torreya grandis stems and leaves as materials, quickly transfer them to a mortar pre-cooled with liquid nitrogen, and grind them into powder; transfer the ground powdered samples to a centrifuge tube, add 500 μL Buffer RCL / 100 mg tissue (EZNA TM Plant RNA Kit), homogenized with a vortexer and mixed by repeated pipetting; incubated at 55°C for 3 min; centrifuged at 15,000g for 5 min, transferred the supernatant to the filter column, and centrifuged at 14,000g for 2 min. Add an equal volume of BufferRCB to the filtrate and invert 5-10 times. Transfer the liquid to the RNA adsorption column and centrifuge at 10,000g for 1 min; discard the filtrate, add 400μL RWCwash Buffer to the adsorption column, and centrifuge at 10,000g for 1 min; dry the adsorption column at room temperature and elute the total RNA with 50μL ddH2O. The integrity of the total RNA was detected by 1.0% non-denaturing agarose gel electrophoresis, and the OD was measured by UV spectrophotometer. 260 / OD 280 ratio and RNA concentration. Using SMARTer TM The first-strand cDNA was synthesized using RACE cDNA amplification kit (Clontech, USA).

[0036] 2. PCR amplification of target gene fragments

[0037] According to the transcriptome information of Torreya grandis, a specific primer pair (SEQ ID NO.3, SEQ ID NO.4) of the candidate gene CsCTS (amino acid sequence as shown in SEQ ID NO.1, nucleotide sequence as shown in SEQ ID NO.2) was designed, and PCR amplification was performed using KOD DNA Polymerase to obtain the full length of the CsCTS gene. The PCR product (target gene fragment) was recovered by gel, connected to the pEASY-blunt vector, transformed into Trans1-T1 competent cells, colony PCR screening was performed, and the positive clones were shaken and sent for sequencing to confirm the sequence information of the candidate gene.

[0038] 2.1 PCR reaction system

[0039]

[0040]

[0041] 2.2 PCR Cycle

[0042] 1) 94℃ 2min; 2) 98℃ 10sec; 3) 58℃ 15sec; 4) 68℃ 2min;

[0043] 5) to 2) 35 cycles; 6) 68℃ 5min; 7) 10℃ hold.

[0044] Example 2: Expression of CsCTS gene, purification of recombinant enzyme and functional identification

[0045] 1. Construction of Rosetta-pET28a-CsCTS recombinant expression strain, induction expression of recombinase and detection

[0046] The pET-28a(+) vector contains a "T7" strong promoter and a "T7" translation initiation signal. The vector contains His tag protein sequences at both the N-terminal and C-terminal. In addition, the vector contains multiple commonly used multiple cloning restriction sites. The His tag can be added to the N-terminal or C-terminal of the target protein for fusion expression as needed.

[0047] According to the gene sequences on both sides of the multi-cloning site of the pET28a(+) vector, primers containing 17bp vector homology arms (SEQ ID NO.5, SEQ ID NO.6) were designed. The homology arms were introduced at the N-terminus and C-terminus of the target gene coding sequence (CDS) by PCR technology, and the PCR products were recovered by gel. The target gene was connected to the linearized pET28a(+) vector using homologous recombinase, and the recombinant plasmid pET28a-CsCTS was constructed. The E. coli (Trans1 T1) cloning host was transformed, and the positive transformants were screened by PCR, and the correctness of the reading frame was identified by sequencing. The correctly sequenced transformants were amplified and cultured, the plasmids were extracted, and the E. coli Rosetta competent cells were transformed, and the positive clones were screened by PCR. The positive transformants were stored at -80°C in 15% glycerol.

[0048] The steps of inducing expression of recombinant enzyme, extracting crude enzyme solution and detecting are as follows: 1) the positive transformants with correct sequences identified by sequencing were inoculated into LB medium containing both kanamycin (pET-28a vector carries resistance) and chloramphenicol (Rosetta host bacteria carries resistance), and cultured at 37°C and 200 rpm for 12 h; 2) the activated seed solution was inoculated into LB (kanamycin) at a ratio of 100:1. + , Chloramphenicol + ) medium, use 250mL Erlenmeyer flasks, each containing 50mL of liquid (use 500mL Erlenmeyer flasks for scale-up experiments, each containing 200mL of liquid); 3) Cultivate at 37°C and 200rpm until OD 600 ≈0.6, add IPTG with a final concentration of 0.2mM to each bottle of culture; induce the expression of the target enzyme at 18℃ and 200rpm; 4), collect the bacteria after 20h of induction culture, centrifuge at 8,000g for 5min, discard the supernatant, and wash the bacteria with ddH2O 1-2 times; 5), add 3mL / g protein extraction buffer (25mM MOPS, 1mM DTT, 10% v / v glycerol, 300mM NaCl, 1mM PMSF, pH 6.8) to the bacteria, vortex to resuspend the precipitate; 6), place the centrifuge tube in an ice bath and ultrasonically disrupt it for 15min (130w, 3s / 3s), and centrifuge at 15,000g for 30min at 4℃ to collect the supernatant, which is the crude enzyme solution.

[0049] 2. Isolation and purification of CsCTS recombinase

[0050] The Rosetta-pET28a-CsCTS recombinant expression strain was used to express the recombinant enzyme and to separate and purify it. The target gene was fused with 6×His tag, and the fusion protein containing the His tag was separated and purified using Ni-TED 6FF (Fast Flow resin) pre-packed column (Shanghai Sangon Biotechnology Co., Ltd.) affinity chromatography column and PD-10 Desalting Columns (GE Healthcare). The specific steps are as follows:

[0051] 2.1. Preparation of buffer

[0052] 1) Binding buffer: 25 mM MOPS buffer, 10% (v / v) glycerol, 300 mM NaCl, pH 6.8;

[0053] 2) Elution buffer: 25 mM MOPS, 300 mM NaCl, 10% (v / v) glycerol, 500 mM imidazole, pH 6.8;

[0054] 3) Desalting buffer: 50mM Tris-HCl, 1mM DTT, 1.5% glycerol, 50mM NaCl, 2.5mMgCl2;

[0055] 4), lysis buffer: binding buffer+1mM PMSF, pH 6.8.

[0056] 2.2 Pretreatment of Ni-TED 6FF prepacked affinity chromatography column

[0057] According to the ratio that each 1mL Ni-TED 6FF column bed can bind to the protein expressed by 2L recombinant strain culture, an affinity chromatography column of appropriate size was selected for column loading, and 10 column volumes of ddH2O, binding buffer, and elution buffer were used for elution in sequence, and finally the column was equilibrated with binding buffer.

[0058] 2.3. Preparation and loading of CsCTS recombinant enzyme crude extract

[0059] The steps of recombinant strain culture and protein induction expression are shown in Part 1 of this embodiment. The induced cultured recombinant bacteria were centrifuged at 8,000g at 4°C to collect the cells, and lysis buffer was added to the cells at a ratio of 3mL / g, and the precipitate was resuspended by vortexing. After ultrasonic disruption in an ice bath for 15min (130w, 3s / 3s), the supernatant was centrifuged at 15,000g for 30min at 4°C, and the supernatant was the crude enzyme extract. The obtained crude enzyme extract was filtered with a 0.45μm filter membrane and loaded into an affinity chromatography column at a flow rate of 1mL / min.

[0060] 2.4. Elution of CsCTS recombinant enzyme

[0061] After loading, the impurities were eluted with 10 column volumes of binding buffer at a flow rate of 1 mL / min. The impurities that were not tightly bound to the column bed were eluted. When the ultraviolet absorption value of the eluent at 280 nm tended to 0, the target protein was eluted. Elution buffers with different imidazole concentrations were prepared for gradient elution of the target protein. The imidazole concentration gradient was as follows: 10 mM, 20 mM, 50 mM, 100 mM. Finally, elution buffer was used for elution. Each concentration gradient was eluted for 5 column volumes, and each flow fraction was detected by SDS-PAGE. The high-purity flow fraction containing the target protein was ultrafiltered and concentrated in an ultrafiltration centrifuge tube (30 kDa, Millipore).

[0062] 2.5. Desalting of CsCTS recombinant enzyme

[0063] The PD-10 Desalting Column was equilibrated with 10 times column volume of pre-cooled ddH2O and desalting buffer respectively. The protein concentrate obtained by ultrafiltration was slowly loaded onto the upper layer of the desalting column. After the sample completely entered the desalting column, it was eluted with desalting buffer and the eluate was received. Each 1 mL was taken as a fraction for SDS-PAGE detection. According to the elution principle of the PD-10 desalting column, the fractions were combined and diluted to an appropriate volume with desalting buffer for protein content determination.

[0064] 3. Functional identification of CsCTS recombinase

[0065] The catalytic function of recombinant CsCTS was identified using GGPP as a substrate. The reaction system is as follows: 10 μg GGPP, 0.2 mg recombinant CsCTS protein, a total reaction volume of 500 μL, reaction buffer (50 mM Tris-HCl, 1 mM DTT, 1.5% glycerol, 50 mM NaCl, 2.5 mM MgCl2), and the reaction was stopped after 12 hours in a 30°C water bath. Extract with n-hexane: take 700 μL of n-hexane, vortex for 20 seconds, let stand for 20 seconds, and repeat 3 times; then, centrifuge at 15,000g for 10 minutes at 4°C, collect the upper n-hexane phase; extract 3 times, collect the n-hexane extract phase, concentrate it, and adjust the volume to 100 μL for GC-MS analysis ( Figure 2 ).

[0066] Example 3: Preparation of the diterpene product cephalotene

[0067] 1. Construction and fermentation of Cephalotene-producing engineered bacteria

[0068] 200 ng of pIRS, 200 ng of pGG and 200 ng of pET28a-CsCTS were co-transformed into E. coli BL21 (DE3). The positive transformants with correct sequences identified by sequencing were inoculated into LB containing three antibiotics (kanamycin + , Chloramphenicol + Spectinomycin + ) medium, shaken at 200 rpm at 37°C for 12 h. The activated seed solution was inoculated into TB (kanamycin) at a ratio of 100:1. + , Chloramphenicol + Spectinomycin + ) medium, select 500mL Erlenmeyer flasks, each containing 200mL of liquid, a total of 20L, and culture at 37℃ for about 2.5h until OD 600 The shaker temperature was lowered to 18°C ​​and cultured for 1 hour, and then a final concentration of 0.2 mM IPTG was added for induction for 72 hours.

[0069] 2. Preparation of Cephalotene (I)

[0070] The recombinant bacterial culture obtained by fermentation was centrifuged at 8,000g at 4°C to collect the bacterial cells and bacterial liquid respectively. The bacterial liquid was extracted 3 times with an equal volume of ethyl acetate and concentrated under reduced pressure to obtain an extract. The bacterial cells were ultrasonically extracted 3 times with methanol, the methanol phase was collected and concentrated under reduced pressure, then dispersed with water, and then extracted 3 times with an equal volume of ethyl acetate and concentrated under reduced pressure to obtain an extract. The two parts of the extract were combined for silica gel column chromatography, eluted with n-hexane, and detected by GC-MS to obtain the product Cephalotene, and optical rotation, UV, IR, MS, NMR and other determinations were performed. Its physical and chemical data are as follows:

[0071] Cephalotene (I): [α] D 20 -10.8 (c = 0.50, CH2Cl2). EI-MS: [M] + m / z = 272. UV (MeOH) λ max (logε) 203 (1.27), 240 (0.55) nm. IR v max 2950, 2924, 2869, 1456, 1441, 1376, 1038 cm -1 . 1 1H NMR (CDCl3, 600 MHz), δ H : 1.82 (2H, t, 9.6 Hz, H-1), 2.83 (m, H-2), 5.41 (d, 8.4 Hz, H-4), 1.86 (m, H-5α), 2.24 (m, H-5β), 1.36 (m, H-6α), 1.48 (m, H-6β), 1.47 (m, H-8α), 0.84 (m, H-8β), 1.26 (m, H-9α), 1.61 (dt, 14.4, 3.6, H-9β), 1.80 (m, H-11), 1.15 (m, H-12α), 0.95 (m, H-12β), 1.46 (m, H-13α), 1.79 (m, H-13β), 2.30 (m, H-14), 1.96 (2H, m, H-15, H-16), 0.86 (3H, s, H-17), 0.74 (3H, d, 6.6, H-18), 0.97 (3H, s, H-19), 1.66 (3H, s, H-20). 13 13C NMR (CDCl3, 150 MHz), δ C : 37.8 (C-1), 43.5 (C-2), 141.0 (C-3), 125.8 (C-4), 22.9 (C-5), 43.2 (C-6), 33.8 (C-7), 31.6 (C-8), 32.0 (C-9), 34.4 (C-10), 29.4 (С-11), 26.0 (C-12), 24.1 (C-13), 34.3 (C-14), 48.2 (C-15), 53.7 (C-16), 26.5 (C-17), 16.6 (C-18), 26.4 (C-19), 24.5 (C-20).

[0072] Example 4: Cephalotene derivative 3,4-dihydroxycephalotene (Ia) Preparation

[0073] 195.6 mg cephalotene (719.7 μmol, 1.0 equiv) was dissolved in a mixed solvent of 3.75 mL t-BuOH and 3.75 mL H2O, and 707.5 mg K3Fe(CN)6 (2159.1 μmol, 3.0 equiv), 297.5 mg K2CO3 (2159.1 μmol, 3.0 equiv), 67.5 mg MeSO2NH2 (719.7 μmol, 1.0 equiv), 25.0 mg K2OsO2(OH)4 (67.8 μmol, 10.0 mol%), and 100.0 mg (DHQD)2PHAL (128.5 μmol, 0.20 mol%) were added. The reaction was stirred at room temperature (23 °C) for 2 d (the reaction process was monitored in real time), and an excess of Na2S2O3 was added and stirred for 10 min to terminate the reaction. The reaction solution was extracted with CH2Cl2 for 3 times, and the combined extracts were dried over Na2SO4, concentrated to dryness under reduced pressure, dissolved with ethyl acetate, evaporated and weighed, and chromatographed on a silica gel column. The eluting phase was petroleum ether: ethyl acetate = 4 / 1. The reaction product was detected by GC-MS, and optical rotation, UV, IR, MS, NMR, etc. were measured; the prepared dihydroxylated product was crystal cultured under the condition of n-hexane: ethyl acetate 10:1, and the obtained single crystal was analyzed by X-ray single crystal diffraction, and the data are as follows:

[0074] 3,4-dihydroxy-cephalotene(Ia):[α] D 20 -21.8 (c=0.44, MeOH); EI-MS: m / z=306[M] + IRv max 3406,2949,2925,2871,1642,1466,1375,1080cm -1 . 1 HNMR (CDCl3, 600MHz),δ H: 2.18 (m, H-1α), 1.72 (m, H-1β), 2.42 (m, H-2), 3.61 (dd, 5.2, 1.6 Hz, H-4), 1.65 (m, H-5α), 1.76 (m, H-5β), 0.95 (m, H-6α), 2.00 (m, H-6β), 1.21 (m, H-8α), 1.07 (m, H-8β), 1.19 (m, H-9α), 1.48 (m, H-9β), 1.66 (m, H-11), 1.73 (m, H-12α), 1.21 (m, H-12β), 1.53 (m, H-13α), 1.73 (m, H-13β), 1.72 (m, H-14), 1.87 (t, 8.0, H-15), 1.51 (m, H-16), 0.84 (3H, s, H-17), 0.72 (3H, d, 6.6, H-18), 0.93 (3H, s, H-19), 1.11 (3H, s, H-20). 13 13C NMR (CDCl3, 150 MHz), δ C : 37.2 (C-1), 43.1 (C-2), 78.1 (C-3), 75.5 (C-4), 24.6 (C-5), 32.3 (C-6), 33.2 (C-7), 33.7 (C-8), 31.6 (C-9), 34.0 (C-10), 30.8 (С-11), 25.8 (C-12), 22.6 (C-13), 33.7 (C-14), 48.7 (C-15), 50.7 (C-16), 24.6 (C-17), 16.1 (C-18), 28.9 (C-19), 20.6 (C-20). Single crystal data: C 20 H 34 O2, 0.375 (H2O) (M = 313.23 g / mol): triclinic, space group P1 (no.1), α = 89.7661(4)°, β = 83.0676(4)°, γ = 80.7903(4)°, Z = 8, T = 100.00(10) K, μ(Cu Kα) = 0.553 mm -1 , Dcalc = 1.132 g / cm 3 , 128486 reflections measured (7.436° ≤ 2Θ ≤ 144.252°), 27337 unique (R int = 0.0312, R sigma=0.0260)which were used in all calculations.Thefinal R1 was 0.0364(I>2σ(I))and wR2 was 0.0941(all data).

[0075] The structure of 3,4-dihydroxycephalosene (Ia) is shown below:

[0076]

[0077] Example 5: Study on the anti-tumor activity of cephalotaxene and 3,4-dihydroxycephalotaxene

[0078] Liver cancer (Huh7), gastric cancer (BGC823), colon cancer (HCT-8), and cervical cancer (HeLa) cells in the logarithmic growth phase were digested with 0.25% trypsin-EDTA and prepared into single-cell suspensions of a certain concentration. According to the difference in cell growth rate, 1500 cells per well were seeded in a 96-well plate, and 100 μl of cell suspension was added to each well. After 24 hours, fresh culture medium containing different concentrations of drugs and corresponding solvent controls was added, and 100 μl (DMSO final concentration <0.1%) was added to each well. Five dose groups were set for each test compound, and paclitaxel was used as the positive control group. At least three parallel wells were set for each group. After continued cultivation at 37°C for 96 hours, the supernatant was discarded, and 100 μl of freshly prepared serum-free culture medium containing 0.5 mg / ml MTT was added to each well. After continued cultivation for 4 hours, the supernatant was discarded, and 150 μl of DMSO was added to each well to dissolve the MTT formazan precipitate. After oscillation and mixing on a micro-oscillator, the optical density (OD) was measured by a microplate reader at a reference wavelength of 450 nm and a detection wavelength of 570 nm. The tumor cells treated with the solvent control were used as the control group to calculate the inhibition rate of the drug on the tumor cells, and the IC was calculated according to the median effect equation. 50 value.

[0079] The results (Table 1) showed that compounds I and Ia had inhibitory activity against the proliferation of human liver cancer cell line Huh7, human gastric cancer cell line BGC823, human colon cancer cell line HCT-8 and human cervical cancer cell line HeLa, respectively.

[0080] Table 1. In vitro cytotoxic activity of compounds I and Ia

[0081]

Claims

1. A compound, characterized in that Having the structure shown in Formula I:

2. Use of the compound according to claim 1 in the preparation of diterpene derivatives, characterized in that: Using the compound as a raw material for preparing diterpenoid derivatives; The diterpenoid derivatives are natural products isolated from plants, preferably from Cephalotaxus plants; or are non-natural compounds artificially synthesized using the compound shown in formula I as a raw material.

3. The use according to claim 2, characterized in that: The carbon skeleton structure of the diterpene derivative is shown in Formula I; Alternatively, the carbon skeleton of the diterpene derivative undergoes carbon reduction, carbon-carbon bond cleavage, carbon chain shift or skeleton rearrangement based on the structure shown in Formula I.

4. The use according to claim 2 or 3, characterized in that: The diterpene derivatives undergo one or more of the following derivatizations based on the carbon skeleton: hydroxylation, carbonylation, carboxylation, esterification, epoxidation, hydrogen removal, aromatization, glycosylation, methylation, acylation, isopentenylation, and reduction.

5. The use according to any one of claims 2 to 4, characterized in that: The diterpene derivatives are prepared by using the compound shown in formula I as a raw material through chemical synthesis and / or biosynthesis.

6. The use according to claim 5, characterized in that: The biosynthesis method is to use the compound shown in formula I as a substrate to carry out an enzyme-catalyzed reaction; the enzyme-catalyzed reaction uses one or a combination of the following enzymes: oxidase, reductase, glycosyltransferase, methyltransferase, acyltransferase, isopentenyltransferase; Preferably, the oxidase is selected from a dehydrogenase, a monooxygenase or a dioxygenase; preferably, the oxidase is selected from a cytochrome P450 enzyme and / or an α-ketoglutarate-dependent dioxygenase.

7. Use of the compound according to claim 1 or its diterpenoid derivatives in the preparation of anti-tumor drugs; The diterpenoid derivatives are natural products isolated from plants, preferably from Cephalotaxus plants; or are non-natural compounds artificially synthesized using the compound shown in formula I as a raw material.

8. The use according to claim 7, characterized in that: The carbon skeleton structure of the diterpene derivative is shown in Formula I; Alternatively, the carbon skeleton of the diterpene derivative undergoes carbon reduction, carbon-carbon bond cleavage, carbon chain shift or skeleton rearrangement based on the structure shown in Formula I.

9. The use according to claim 7 or 8, characterized in that: The diterpene derivatives undergo one or more of the following derivatizations based on the carbon skeleton: hydroxylation, carbonylation, carboxylation, esterification, epoxidation, hydrogen removal, aromatization, glycosylation, methylation, acylation, isopentenylation, and reduction.

10. The use according to any one of claims 7 to 9, characterized in that: The anti-tumor drug has cytotoxic activity against liver cancer, stomach cancer, colon cancer and / or cervical cancer cells.